Standout Papers

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase... 2023 2026 2024175
  1. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies (2023)
    William J. Sandborn, Séverine Vermeire et al. The Lancet

Immediate Impact

10 from Science/Nature 91 standout
Sub-graph 1 of 22

Citing Papers

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025 Standout
Engineered commensals for targeted nose-to-brain drug delivery
2025 Standout
27 intermediate papers

Works of Kevin Shan being referenced

Pramlintide Improved Measures of Glycemic Control and Body Weight in Patients With Type I Diabetes Mellitus Undergoing Continuous Subcutaneous Insulin Infusion Therapy
2013
Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy
2009
and 1 more

Author Peers

Author Last Decade Papers Cites
Kevin Shan 74 9 44 190 164 18 565
Kavaljit H. Chhabra 154 2 7 117 101 27 560
J.F. Gautier 105 5 11 162 67 21 514
Jefferson P. Lomenick 94 20 28 131 101 20 559
Porsha Smith 215 9 13 102 54 17 649
Alexandre Fisette 105 9 7 190 112 26 513
R. De Iasio 65 11 5 107 137 15 540
Z. Hochberg 145 79 22 150 59 31 594
Stefanie Graf 54 19 40 121 214 10 491
Robert M. Walter 83 33 36 120 55 26 604
Adam Buckley 129 30 7 181 67 26 565

All Works

Loading papers...

Rankless by CCL
2026